Moderna extends its rally on Nasdaq, analysts lift targets as shares clear the 67 dollar mark

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-29, 10:53.

Moderna Inc. (US60770K1034) has extended its recent rally on the Nasdaq, with MRNA shares clearing the 67 dollar mark after a series of bullish pipeline headlines and fresh analyst price target moves this week, according to Nasdaq data and consensus compilations. The stock has gained more than 40 percent over the past month as tracked by TrendSpider, putting it among the stronger performers in the S&P 500 healthcare cohort.

What the rally looks like

On Friday, Moderna closed around 67.27 dollars on Nasdaq, up roughly 12.6 percent on the day, according to Public.com's real-time quote for MRNA. TrendSpider's market data shows the shares at 67.33 dollars, with a one-day gain of 12.69 percent and a roughly 42.7 percent increase over the past 30 days.

Finanzen100 highlights that MRNA was up about 13 percent in one recent session on reports of in vivo CAR-T progress and flu vaccine developments, while a separate dispatch noted a roughly 15 percent surge following a broader business update that emphasized cancer and autoimmune pipeline ambitions. The stock's move has come on elevated trading volumes earlier in the week, though TrendSpider now flags below-average volume over the past 30 days despite the price advance.

Analysts adjust their view

Analyst sentiment on Moderna has shifted in recent days as the shares climbed, with several houses reiterating or adjusting their ratings and targets, according to MarketScreener's overview of recent MRNA research actions. Piper Sandler reaffirmed its Buy recommendation on June 26 and lifted its price target to 77 dollars, signalling a constructive stance on the medium-term upside potential.

Jefferies maintains a Neutral view on the stock, while Leerink Partners continues to rate Moderna at Sell, according to the same MarketScreener summary of analyst moves. Intellectia.ai, citing Wall Street analyst forecasts, reports that the broader coverage includes around 20 ratings with a skew toward Hold, capturing the cautious tone of part of the street even as the shares rally. At the same time, Finanzen100 points to market commentary discussing whether Moderna's recent double-digit percentage gains are now outpacing other vaccine-exposed names such as Merck and Pfizer.

Pipeline drivers behind sentiment

The rally has coincided with a series of pipeline-related headlines. MarketScreener cites a June 23 note that an FDA advisory committee gave a unanimous recommendation for Moderna's mRNA-based flu vaccine for adults aged 50 and older, a key step toward potential approval in a sizeable indications market. Benzinga and Bloomberg have reported that the FDA scheduled and held a rare advisory hearing around the flu shot, underscoring the regulatory focus on the program and the transparency of the review process.

Finanzen100 points to investor enthusiasm about Moderna's work on in vivo CAR-T therapies, which could extend its mRNA platform into oncology applications beyond classic vaccines. The same coverage mentions an expanded focus on cancer and autoimmune conditions in the company's pipeline, with a business update earlier in the week explicitly outlining an ambition to diversify revenues away from the pandemic-driven COVID-19 franchise. Intellectia.ai summarises this strategic shift as Moderna "expanding beyond COVID vaccines" in its framing of the recent 42 percent share move.

How Moderna makes its money

Moderna's business model is built around its mRNA platform, with commercial revenues still driven largely by the Spikevax COVID-19 vaccine and associated booster campaigns in key markets. In parallel, the company is advancing a respiratory portfolio that includes its mRNA flu candidate and other respiratory syncytial virus and combination vaccine programs, as highlighted in recent FDA and market coverage.

Beyond infectious diseases, Moderna is investing in oncology and autoimmune pipeline assets that apply its mRNA technology to therapeutic protein expression and personalised cancer vaccines, a direction that featured prominently in the recent business update cited by Finanzen100. The company's strategy aims to translate this diversified pipeline into a more balanced revenue base over the medium term as COVID-related demand normalises.

Where the MRNA shares trade today

Moderna shares (US60770K1034) trade on Nasdaq at 67.27 dollars as of 2026-06-26, 21:59, according to Public.com's quoted closing price for MRNA.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation or a solicitation to buy or sell any financial instrument. Figures and dates are based on sources cited and may change over time.